Company

Adicet Bio, Inc.

Headquarters: Menlo Park, CA, United States

Employees: 86

CEO: Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA

NASDAQ: ACET -1.50%

Market Cap

$76.0 Million

USD as of Jan. 1, 2025

Market Cap History

Adicet Bio, Inc. market capitalization over time

Evolution of Adicet Bio, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Adicet Bio, Inc.

Detailed Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Dec. 31, 2023
Revenue TTM $0
EBITDA $-126,478,000
Gross Profit TTM $0
Profit Margin 0.00%
Operating Margin 0.00%
Quarterly Revenue Growth %
Financial Reports & Statistics

Stocks & Indices

Adicet Bio, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ACET wb_incandescent

Stock: FSX: 1IJA wb_incandescent

Details

Headquarters:

200 Constitution Drive

Menlo Park, CA 94025

United States

Phone: 857 315 5528